Search by category
1. What other type of treatment do you want to administer concomitantly?
Anti-infective agents
Drugs for digestive disorders
Drugs for endocrine and cardiovascular disorders
Analgesics and opioids
Antidepressants and antipsychotics
Complementary alternative medicine
2. In which category is the drug you want to administer concomitantly?
Information about interaction with CYP3A1
| STRONG INHIBITOR | MODERATE INHIBITOR | WEAK INHIBITOR | STRONG INDUCTOR | MODERATE INDUCTOR | WEAK INDUCTOR | |
|---|---|---|---|---|---|---|
| Effect on the sensitive index substrate (SS) | SS AUC increases 5 times | SS AUC increases from ≥2 to <5 times | SS AUC increases from ≥1.25 to <2 times | SS AUC decreases ≥80% | SS AUC decreases from ≥50% to <80% | SS AUC decreases from ≥20% to <50% |
| Clinical significance | Toxicity monitoring | Low risk of DDI | Low risk of DDI | Efficacy monitoring | Efficacy monitoring | Low risk of DDI |
| Recommendations | Consider lowering the substrate dose | Monitoring | None | Consider increasing the sustrate dose | Monitoring | None |
AUC: area under the curve; DDI: drug-drug interaction.
1. Bellet M, et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med
Oncol. 2019 May 10;11:1758835919833867. doi: 10.1177/1758835919833867.
